KV
Krishna Vaddi
CEO

Krishna Vaddi insider trades: Prelude Therapeutics (PRLD) stock purchases

CEO, Prelude Therapeutics Last trade Mar 25, 2025 18 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2022
1
Company
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Krishna reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Mar 25, 2025PRLD↑ Buy$467K
Mar 21, 2025PRLD↑ Buy$15K
Mar 17, 2025PRLD↑ Buy$29K
Mar 13, 2025PRLD↑ Buy$70K
Dec 31, 2024PRLD↑ Buy$6K
Dec 30, 2024PRLD↑ Buy$12K
Dec 19, 2024PRLD↑ Buy$6K
Dec 18, 2024PRLD↑ Buy$93K
May 25, 2023PRLD↑ Buy$10K
May 23, 2023PRLD↑ Buy$67K
Dec 20, 2022PRLD↑ Buy$98K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Krishna Vaddi's insider trades

Krishna Vaddi is CEO at Prelude Therapeutics (PRLD). Since Dec 20, 2022, Krishna has reported 11 open-market purchases worth $874K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (7 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PRLD insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.